查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2005109

次世代定序(NGS) CLIA 檢測服務市場：按服務類型、應用、最終用戶、技術平台和檢體類型分類－2026-2032 年全球市場預測

Next Generation Sequencing CLIA Laboratory Services Market by Service Type, Application, End User, Technology Platform, Sample Type - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，次世代定序(NGS) CLIA 偵測服務市值將達到 77.1 億美元，到 2026 年將成長至 88.1 億美元，到 2032 年將達到 192.1 億美元，複合年成長率為 13.92%。

主要市場統計數據
基準年 2025 77.1億美元
預計年份：2026年 88.1億美元
預測年份 2032 192.1億美元
複合年成長率 (%) 13.92%

對重組 CLIA 認證的次世代定序檢查室服務的營運現實和策略挑戰進行了引人入勝的概述。

臨床分子診斷領域正迅速走向成熟，次世代定序(NGS)調查方法日益融入常規臨床工作流程。本執行摘要全面而實用地觀點了 CLIA 認證的 NGS 檢測服務的發展現狀、重塑服務交付的技術和營運轉折點，以及領導者為保持競爭力應考慮的戰略選擇。摘要還闡述了臨床EXOME、標靶基因panel和全基因組策略在不斷變化的支付方期望、日益嚴格的監管以及對精準醫療日益成長的需求等因素共同作用下的商業環境。

展望未來，概述技術、監管和營運方面的變化，這些變化將重新定義次世代定序服務的交付和夥伴關係。

由於多種因素的共同作用，基於次世代定序的CLIA認證檢查室服務格局正在經歷一場變革。儘管技術進步降低了高通量定序的進入門檻，但分析的複雜性卻日益增加，迫使檢查室迅速改善檢測設計、檢驗框架和資訊處理流程。新的定序平台和化學技術的改進正在改變人們對通量經濟性和數據品質的考量，進而影響著標靶基因組定序、EXOME序和全基因組檢測等臨床檢測方法的選擇。

對近期關稅調整如何重塑臨床 NGS檢查室的採購韌性、營運連續性和供應商策略進行嚴格分析。

美國將於2025年實施新的關稅措施，將對依賴全球供應鏈的CLIA認證的次世代定序檢查室產生即時且連鎖的影響。進口試劑、耗材和儀器組件的關稅將增加單位成本，並使長期採購計畫更加複雜。先前基於可預測的供應商價格最佳化成本結構的檢查室，現在需要評估其成本基礎對關稅波動的敏感性，並考慮避險策略、多供應商採購或近岸外包等措施來降低風險。

對決定操作和解釋複雜性的服務類型、臨床應用、最終用戶、平台技術和檢體相關因素進行詳細分析。

深入的細分揭示了臨床價值與操作複雜性在服務類型、應用、最終用戶、技術平台和檢體類型之間的交集。服務類型（臨床EXOME序、標靶基因panel檢測和全基因組定序）的差異體現在檢驗負擔和臨床報告要求的不同。臨床EXOME定序方法分為成人和兒童EXOME，需要專門的解讀流程以及不同的知情同意和變異註釋實踐。同時，針對癌症、心血管疾病和神經系統疾病的標靶基因panel檢測為特定的臨床效用提供了可擴展的方法。在癌症panel檢測中，血液系統惡性腫瘤panel和固態腫瘤panel之間的區別導致了不同的檢體處理要求和生物資訊工作流程，檢查室必須仔細考慮這些差異。

對全球主要地區臨床基因組學服務的監管細微差別、檢體獲取趨勢和獲取途徑進行區域分析。

地理因素持續影響美洲、歐洲、中東、非洲和亞太地區定序平台的取得、試劑供應鏈、監管解讀以及臨床應用率，導致各地區檢查室的策略重點有所不同。在美洲，綜合醫療保健系統和先進的腫瘤中心正在推動對伴隨診斷和高複雜度定序服務的需求，而法規環境強調CLIA認證和與保險公司的合作，以實現臨床認可和規模化應用。

對決定臨床定序服務競爭優勢的供應商定位、整合解決方案策略和夥伴關係模式進行詳細分析。

主要企業之間的競爭格局取決於其技術組合的廣度、全球製造和供應鏈的穩健性、試劑和耗材生態系統，以及生物資訊學和臨床報告支援的全面性。領先的定序平台供應商不僅在先導化合物的準確性和通量上競爭，還在下游服務（例如檢測試劑盒、參考資料資料庫和整合資訊學解決方案）方面競爭，這些服務能夠降低臨床檢驗的時間和成本。平台供應商與診斷檢查室之間的策略夥伴關係，透過協調檢驗流程和供應保障，加速了檢測部署；而投資於試劑可靠性和​​本地化生產的公司，則在供應緊張的情況下獲得了營運優勢。

檢查室經營團隊的可操作策略重點，重點在於採購彈性、臨床差異化和可擴展的卓越營運。

產業領導者必須採取雙管齊下的策略，在短期營運韌性和長期臨床差異化之間取得平衡。首先，優先考慮供應商多元化和長期合約結構，以抵禦供應鏈波動和關稅影響。這包括評估替代供應商、建立本地生產夥伴關係以及製定庫存策略，以確保臨床服務的連續性。其次，投資於模組化自動化和標準化品質體系，以加快檢測檢驗、降低錯誤率並支援可擴展的吞吐量，同時確保臨床解讀的嚴謹性。

透明的調查方法，結合與關鍵相關人員的訪談、技術檢驗審查和基於場景的壓力測試，為營運實施提供可操作的見解。

本研究整合了與關鍵相關人員（包括檢查室管理人員、平台供應商、臨床相關人員和專家）的對話，並系統地回顧了監管指南、同行評審文獻和供應商技術文檔，從而得出全面而實用的評估。調查方法強調三角驗證：定性訪談反映實際操作情況，技術檢驗和通訊協定審查揭示檢測性能的局限性，平台規格的比較分析則確定與臨床實施相關的權衡取捨。

一項旨在促進臨床基因組學服務永續發展的策略執行、供應商韌性和臨床證據途徑的全面整合。

總而言之，CLIA認證的次世代定序檢查室服務正處於一個轉折點，技術進步、供應鏈趨勢、監管預期和不斷演變的臨床應用模式在此交匯，既帶來了挑戰，也帶來了機會。積極提升採購韌性、投資建構強大的生物資訊學解讀框架、並與平台供應商和臨床相關人員建立夥伴關係的檢查室，將更有能力將技術能力轉化為可靠且具有臨床實用性的服務。標靶基因組定序、EXOME序和全基因組檢測的相互作用，需要從組合角度出發，使檢測選擇與臨床效用、營運能力和監管要求一致。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章次世代定序(NGS) CLIA 偵測服務市場：依服務類型分類

  • 臨床EXOME定序
    • 成人EXOME
    • 兒童EXOME
  • 標靶基因檢測
    • 癌症小組
      • 血液疾病檢測
      • 固態腫瘤組
    • 心血管小組
    • 神經系統疾病組
  • 全基因組定序

第9章次世代定序(NGS) CLIA 偵測服務市場：依應用領域分類

  • 感染疾病
    • 細菌感染疾病
    • 病毒感染疾病
  • 遺傳性疾病
    • 一般疾病
    • 罕見疾病
  • 腫瘤學
    • 骨髓惡性腫瘤
    • 固態腫瘤
  • 藥物基因體學
  • 生殖醫學
    • 非侵入性產前檢測
    • 胚胎著床前遺傳學檢測

第10章次世代定序(NGS) CLIA 偵測服務市場：依最終使用者分類

  • 診斷檢測實驗室
  • 消費者測試
  • 醫院和診所
  • 研究機構

第11章 按技術平台分類的次世代定序(NGS) CLIA 檢測服務市場

  • 華大基定序平台
    • BGI-Seq 500
    • Mgiseq
  • Illumina定序平台
    • MiSeq
    • NextSeq
    • NovaSeq
  • Thermo Fisher定序平台
    • Ion Torrent PGM
    • Ion Torrent Proton

第12章次世代定序(NGS) CLIA 檢測服務市場（檢體類型分類）

  • 血
    • 電漿
    • 全血
  • 唾液
  • 組織
    • FFPE
    • 新鮮冷凍

第13章次世代定序(NGS) CLIA 偵測服務市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章次世代定序(NGS) CLIA 偵測服務市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章次世代定序(NGS) CLIA 檢測服務市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國次世代定序(NGS) CLIA 偵測服務市場

第17章：中國次世代定序（NGS）CLIA檢測服務市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Adaptive Biotechnologies Corporation
  • Agilent Technologies Inc
  • ARUP Laboratories
  • Azenta Life Sciences
  • BGI Genomics Co Ltd
  • Bio-Rad Laboratories Inc
  • Charles River Laboratories Inc
  • Eurofins Scientific SE
  • F Hoffmann-La Roche AG
  • Foundation Medicine Inc
  • Fulgent Genetics Inc
  • Guardant Health Inc
  • Illumina Inc
  • Invitae Corporation
  • IQVIA Laboratories
  • Macrogen Inc
  • Myriad Genetics Inc
  • Natera Inc
  • NeoGenomics Laboratories
  • Novogene Corporation
  • Oxford Nanopore Technologies plc
  • Personalis Inc
  • QIAGEN NV
  • Quest Diagnostics Incorporated
  • Thermo Fisher Scientific Inc
  • Veracyte Inc
Product Code: MRR-C41945B3D381

The Next Generation Sequencing CLIA Laboratory Services Market was valued at USD 7.71 billion in 2025 and is projected to grow to USD 8.81 billion in 2026, with a CAGR of 13.92%, reaching USD 19.21 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 7.71 billion
Estimated Year [2026] USD 8.81 billion
Forecast Year [2032] USD 19.21 billion
CAGR (%) 13.92%

A compelling introduction to the operational realities and strategic imperatives reshaping CLIA-certified next generation sequencing laboratory services

The clinical molecular diagnostics landscape is entering a phase of accelerated maturation where next generation sequencing (NGS) methodologies are increasingly embedded in routine clinical workflows. This executive summary introduces a comprehensive and pragmatic view of how CLIA-certified NGS laboratory services are evolving, the technology and operational inflection points reshaping service delivery, and the strategic choices leaders must deliberate to remain competitive. It frames the business context in which clinical exome, targeted gene panels, and whole genome strategies coexist alongside shifting payer expectations, tighter regulatory scrutiny, and rising demand for precision therapeutics.

Transitioning from development to clinical scale requires an integrated perspective that spans technology platform selection, sample logistics, bioinformatics pipelines, and quality management systems. The Introductory section therefore situates readers within the operational realities of accredited laboratories, highlighting how end users-from hospitals to direct-to-consumer channels-are changing requisition patterns and expectations for turnaround, interpretive clarity, and clinical utility. By focusing on pragmatic change drivers rather than abstract projections, this section prepares decision-makers to interpret subsequent insights and to prioritize investments that yield measurable clinical and commercial returns.

A forward-looking synthesis of technological, regulatory, and operational shifts redefining clinical next generation sequencing service delivery and partnerships

The landscape for CLIA laboratory services powered by next generation sequencing is undergoing transformative shifts driven by several converging forces. Technological progress is lowering the barrier to high-throughput sequencing while simultaneously increasing analytical complexity, compelling laboratories to iterate rapidly on assay design, validation frameworks, and informatics pipelines. Newer sequencing platforms and chemistry refinements are changing throughput economics and data quality considerations, which in turn affect clinical assay choices between targeted panels, exome approaches, and whole genome testing.

Alongside technology, regulatory and reimbursement environments are evolving. Laboratories are adapting to more stringent validation expectations, transparency around variant interpretation, and the need for robust clinical evidence to support diagnostic claims. Payer policies are increasingly focused on demonstrable clinical utility and value-based outcomes, prompting laboratories to emphasize assay standardization, clinical reporting consistency, and longitudinal data collection. Concurrently, the rise of precision oncology and the integration of genomic data into electronic health records are driving tighter collaboration between diagnostic providers, hospitals, and therapeutics developers, creating new service models such as companion diagnostics and longitudinal genomic surveillance.

Operationally, workforce constraints and the need for specialized bioinformatics expertise are catalyzing partnerships with external data providers and software vendors, while quality accreditation and scalability considerations drive laboratories to invest in automation, laboratory information management systems, and cloud-enabled pipelines. Taken together, these shifts mandate a strategic balancing act: adopting innovations that deliver clinical differentiation while ensuring compliance, cost control, and reproducibility in high-volume, regulated environments.

A rigorous analysis of how recent tariff adjustments reshape procurement resilience, operational continuity, and supplier strategies for clinical NGS laboratories

The implementation of new tariff measures in the United States in 2025 introduces immediate and cascading implications for CLIA-certified next generation sequencing laboratories that rely on global supply chains. Tariffs on imported reagents, consumables, and equipment components increase unit costs and complicate long-term procurement planning. Laboratories that previously optimized cost structures around predictable vendor pricing must now evaluate the sensitivity of their cost base to duty fluctuations and consider hedging strategies, multi-sourcing, or nearshoring to mitigate exposure.

Supply chain disruptions are another direct consequence, with extended lead times and allocation risks prompting laboratory managers to reassess inventory policies, safety stock levels, and supplier contracts. In certain instances, laboratories may face prioritization dilemmas when critical reagents or platform components become constrained, forcing a re-evaluation of test menus, throughput commitments, and clinical prioritization frameworks. These operational trade-offs have implications for turnaround time commitments and customer relationships, particularly for high-acuity services such as oncology panels and prenatal diagnostics.

The tariff environment also reshapes competitive positioning. Vendors with diversified manufacturing footprints or domestic production capabilities gain relative advantage, while smaller suppliers dependent on cross-border supply chains may experience margin compression or exit pressures. For laboratories, this means procurement strategies must increasingly incorporate supplier resilience metrics and total landed cost analyses rather than purely unit price comparisons. Additionally, the tariff context incentivizes collaborative approaches with sequencing platform manufacturers and reagent suppliers to secure long-term supply agreements, co-developed pricing models, or localized manufacturing arrangements that preserve service continuity and cost predictability.

Regulatory and compliance frameworks intersect with tariffs in nuanced ways. Changes to import regimes can affect lead times for validated components, necessitating revalidation efforts where alternates or substitute reagents are introduced. Laboratories must therefore build flexible validation pathways and ramp testing protocols that allow controlled substitution without compromising clinical integrity. In sum, the 2025 tariff adjustments force a strategic reorientation across procurement, operations, quality assurance, and commercial engagement to sustain service reliability and maintain margins under greater supply-chain volatility.

A granular exploration of service type, clinical application, end user, platform technology, and sample considerations that determine operational and interpretive complexity

Insightful segmentation illuminates where clinical value and operational complexity intersect across service type, application, end user, technology platform, and sample type. Service type distinctions among clinical exome sequencing, targeted gene panel testing, and whole genome sequencing reveal different validation burdens and clinical reporting demands; clinical exome efforts split between adult and pediatric exomes require specialized interpretive pipelines and distinct consent and variant curation practices, while targeted gene panels such as cancer, cardiovascular, and neurological disorder panels present scalable pathways for focused clinical utility. Within cancer panels, the distinction between hematologic panels and solid tumor panels creates divergent specimen processing requirements and bioinformatics workflows that laboratories must explicitly address.

Application-level segmentation underscores varied clinical evidence needs and specimen workflows. Infectious disease testing divides into bacterial and viral workflows with unique nucleic acid extraction and contamination control considerations, whereas inherited disease testing spans common conditions suitable for higher-throughput approaches and rare disease analyses that demand deep variant curation and multidisciplinary case review. Oncology applications bifurcate into hematologic malignancies and solid tumors, each with differing tissue handling demands and variant interpretation frameworks. Reproductive health applications, ranging from noninvasive prenatal testing to preimplantation genetic testing, impose stringent pre-analytic controls and counseling pathways that laboratories must operationalize.

End user segmentation differentiates service delivery models and commercial interfaces. Diagnostic laboratories, direct-to-consumer testing channels, hospitals and clinics, and research institutes each present unique requisition workflows, reporting expectations, and compliance obligations, requiring laboratories to calibrate client service models accordingly. Technology platform choices among BGI, Illumina, and Thermo Fisher sequencing platforms necessitate vendor-specific validation strategies and throughput planning; within these families, instrument variants such as Bgiseq 500, Mgiseq, MiSeq, NextSeq, NovaSeq, and Ion Torrent models introduce discrete technical and logistical considerations. Sample type segmentation across blood, saliva, and tissue embodies divergent pre-analytic and storage needs, where blood subsets like plasma versus whole blood and tissue formats such as FFPE versus fresh frozen demand tailored extraction and quality assessment procedures. Collectively, these layered segments define the operational playbook laboratories must design to ensure assay reliability, interpretive clarity, and fit-for-purpose clinical deployment.

A regional analysis of regulatory nuance, procurement dynamics, and adoption pathways shaping clinical genomic services across major global regions

Geographic dynamics continue to shape access to sequencing platforms, reagent supply chains, regulatory interpretations, and clinical adoption rates across the Americas, Europe Middle East & Africa, and Asia-Pacific, creating differentiated strategic priorities for laboratories operating in each region. In the Americas, integrated health systems and pockets of advanced oncology care drive demand for companion diagnostics and high-complexity sequencing services, while the regulatory environment emphasizes CLIA accreditation and payer engagement to achieve clinical acceptance and scaling.

Across Europe, the Middle East and Africa, heterogeneity in regulatory frameworks and reimbursement policies generates a patchwork market where laboratories must navigate divergent national requirements and data protection regimes. This environment favors flexible service models, partnerships with regional reference labs, and investments in localized clinical evidence to support adoption. In the Asia-Pacific region, rapid platform uptake, significant local manufacturing presence, and ambitious public health sequencing initiatives are catalyzing growth, but laboratories must manage complex logistics, multilingual reporting requirements, and variable reimbursement mechanisms to translate capability into sustainable clinical services.

The regional differences also influence talent availability, automation adoption, and laboratory consolidation trends. Markets with constrained skilled bioinformatics and clinical genetics capacity often rely more heavily on centralized reference labs or cloud-based interpretive services, whereas regions with concentrated specialist centers can support decentralized offerings and closer hospital-laboratory integration. Understanding regional regulatory nuances, procurement cycles, and clinical referral patterns enables laboratories to tailor go-to-market strategies that align with local demand signals and operational realities.

An in-depth look at vendor positioning, integrated solution strategies, and partnership models that determine competitive advantage in clinical sequencing services

Competitive dynamics among key companies are defined by technology portfolio breadth, global manufacturing and supply resilience, reagent and consumable ecosystems, and the depth of bioinformatics and clinical reporting support. Leading sequencing platform providers compete not only on read accuracy and throughput but also on downstream services such as assay kits, reference databases, and integrated informatics offerings that reduce the time and cost to clinical validation. Strategic partnerships between platform vendors and diagnostic laboratories accelerate assay adoption by aligning validation pathways and supply assurances, while companies investing in reagent reliability and localized production gain operational advantages under constrained supply conditions.

In parallel, companies that offer integrated solutions encompassing sample-to-report workflows, regulatory support, and clinician-facing interpretive tools are increasingly valued by laboratories seeking to shorten deployment timelines and minimize internal development overhead. The emergence of specialized players delivering curated variant databases, clinical decision support, and regulatory-ready documentation creates an ecosystem where laboratories can assemble best-of-breed components or adopt end-to-end solutions depending on strategic priorities. Competitive differentiation also arises from services tailored to high-value clinical applications such as oncology and reproductive health, where the ability to demonstrate clinical validity, report clarity, and actionable recommendations influences purchasing and referral decisions.

Finally, nimble vendors that provide flexible commercial models-subscription-based informatics, reagent-as-a-service, or collaborative validation programs-are well-positioned to support laboratories through technology transitions and regulatory change. As consolidation and strategic alliances continue, laboratories should evaluate partners based on technical performance, supply chain resilience, and the capacity to co-develop clinical workflows that align with institutional objectives.

Actionable strategic priorities for laboratory executives focused on procurement resilience, clinical differentiation, and scalable operational excellence

Industry leaders must pursue a dual strategy that balances near-term operational resilience with long-term clinical differentiation. First, prioritize supplier diversification and long-term contractual arrangements to protect against supply chain volatility and tariff impacts; this includes evaluating alternative vendors, localized manufacturing partnerships, and inventory strategies that preserve clinical continuity. Second, invest in modular automation and standardized quality systems that accelerate assay validation, reduce error rates, and support scalable throughput without sacrificing clinical interpretive rigor.

Third, strengthen bioinformatics and variant interpretation capabilities through a combination of internal talent development and external partnerships, ensuring reproducible pipelines, transparent curation policies, and clinician-friendly reporting. Fourth, deepen engagement with payers and clinicians to build evidence of clinical utility and pathway integration, focusing on high-impact applications such as oncology panels and reproductive health testing where diagnostic decisions directly inform care. Fifth, adopt flexible commercial models and customer support offerings that align with different end-user expectations-from hospitals requiring integrated EHR reporting to direct-to-consumer channels seeking simplified results and counseling frameworks.

Finally, embed regulatory foresight into strategic planning by cultivating capabilities for rapid revalidation, documentation management, and audit readiness. Leaders should also consider collaborative approaches with platform vendors and peer laboratories to share validation burden, harmonize reporting standards, and accelerate adoption of best practices. These combined actions will enable organizations to preserve service reliability, enhance clinical credibility, and capture opportunities created by evolving care pathways and technology advances.

A transparent methodology combining primary stakeholder interviews, technical validation review, and scenario stress-testing to inform operationally actionable insights

This research synthesizes primary engagements with laboratory leaders, platform vendors, clinical stakeholders, and subject-matter experts, combined with systematic review of regulatory guidance, peer-reviewed literature, and vendor technical documentation to produce a comprehensive and practical assessment. The methodology emphasizes triangulation: qualitative interviews contextualize operational realities, technical validations and protocol reviews illuminate assay performance constraints, and comparative analyses of platform specifications identify trade-offs relevant to clinical deployment.

Quality assurance in the research process included cross-validation of interpretive frameworks with practicing clinical geneticists and laboratory directors, and scenario stress-testing of procurement and supply-chain responses to tariff changes. The research also incorporated detailed mapping of sample workflows across specimen types-blood, saliva, and tissue-to identify pre-analytic vulnerabilities and mitigation strategies. Where possible, evidence was prioritized that reflects clinical workflows and regulatory compliance needs rather than marketing claims, ensuring that recommendations are implementable and aligned with accreditation requirements.

Analytical approaches focused on decomposing operational costs into process-level activities, evaluating validation timelines for different assay classes, and assessing vendor resilience across manufacturing footprints. Throughout, confidentiality and ethical considerations guided primary data collection, and methodologies were designed to be transparent and reproducible so that organizations can adapt the approach for their internal audits and strategic planning exercises.

A conclusive synthesis emphasizing strategic execution, supplier resilience, and clinical evidence pathways that enable sustainable growth in clinical genomics services

In conclusion, CLIA-certified next generation sequencing laboratory services are at an inflection point where technology advances, supply-chain dynamics, regulatory expectations, and shifting clinical adoption patterns converge to create both challenges and opportunities. Laboratories that proactively address procurement resilience, invest in robust bioinformatics and interpretive frameworks, and cultivate partnerships with platform vendors and clinical stakeholders will be best positioned to translate technological capability into reliable, clinically actionable services. The interplay between targeted panels, exome approaches, and whole genome testing requires a portfolio mindset that aligns assay choice with clinical utility, operational capacity, and regulatory obligations.

Furthermore, regional dynamics and tariff-related supply risks underscore the necessity for flexible validation pathways and diversified sourcing strategies. Companies and laboratories that prioritize quality systems, clinician engagement, and payer evidence-building can accelerate adoption while maintaining compliance and trust. Ultimately, success in this sector will hinge on disciplined execution across laboratory processes, strategic supplier relationships, and a relentless focus on delivering clear clinical value that integrates seamlessly into patient care pathways.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Next Generation Sequencing CLIA Laboratory Services Market, by Service Type

  • 8.1. Clinical Exome Sequencing
    • 8.1.1. Adult Exome
    • 8.1.2. Pediatric Exome
  • 8.2. Targeted Gene Panel Testing
    • 8.2.1. Cancer Panels
      • 8.2.1.1. Hematologic Panels
      • 8.2.1.2. Solid Tumor Panels
    • 8.2.2. Cardiovascular Panels
    • 8.2.3. Neurological Disorder Panels
  • 8.3. Whole Genome Sequencing

9. Next Generation Sequencing CLIA Laboratory Services Market, by Application

  • 9.1. Infectious Disease
    • 9.1.1. Bacterial Infections
    • 9.1.2. Viral Infections
  • 9.2. Inherited Disease
    • 9.2.1. Common Disease
    • 9.2.2. Rare Disease
  • 9.3. Oncology
    • 9.3.1. Hematologic Malignancies
    • 9.3.2. Solid Tumor
  • 9.4. Pharmacogenomics
  • 9.5. Reproductive Health
    • 9.5.1. Noninvasive Prenatal Testing
    • 9.5.2. Preimplantation Genetic Testing

10. Next Generation Sequencing CLIA Laboratory Services Market, by End User

  • 10.1. Diagnostic Laboratories
  • 10.2. Direct To Consumer Testing
  • 10.3. Hospitals And Clinics
  • 10.4. Research Institutes

11. Next Generation Sequencing CLIA Laboratory Services Market, by Technology Platform

  • 11.1. BGI Sequencing Platforms
    • 11.1.1. Bgiseq 500
    • 11.1.2. Mgiseq
  • 11.2. Illumina Sequencing Platforms
    • 11.2.1. MiSeq
    • 11.2.2. NextSeq
    • 11.2.3. NovaSeq
  • 11.3. Thermo Fisher Sequencing Platforms
    • 11.3.1. Ion Torrent Pgm
    • 11.3.2. Ion Torrent Proton

12. Next Generation Sequencing CLIA Laboratory Services Market, by Sample Type

  • 12.1. Blood
    • 12.1.1. Plasma
    • 12.1.2. Whole Blood
  • 12.2. Saliva
  • 12.3. Tissue
    • 12.3.1. Ffpe
    • 12.3.2. Fresh Frozen

13. Next Generation Sequencing CLIA Laboratory Services Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Next Generation Sequencing CLIA Laboratory Services Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Next Generation Sequencing CLIA Laboratory Services Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Next Generation Sequencing CLIA Laboratory Services Market

17. China Next Generation Sequencing CLIA Laboratory Services Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Adaptive Biotechnologies Corporation
  • 18.6. Agilent Technologies Inc
  • 18.7. ARUP Laboratories
  • 18.8. Azenta Life Sciences
  • 18.9. BGI Genomics Co Ltd
  • 18.10. Bio-Rad Laboratories Inc
  • 18.11. Charles River Laboratories Inc
  • 18.12. Eurofins Scientific SE
  • 18.13. F Hoffmann-La Roche AG
  • 18.14. Foundation Medicine Inc
  • 18.15. Fulgent Genetics Inc
  • 18.16. Guardant Health Inc
  • 18.17. Illumina Inc
  • 18.18. Invitae Corporation
  • 18.19. IQVIA Laboratories
  • 18.20. Macrogen Inc
  • 18.21. Myriad Genetics Inc
  • 18.22. Natera Inc
  • 18.23. NeoGenomics Laboratories
  • 18.24. Novogene Corporation
  • 18.25. Oxford Nanopore Technologies plc
  • 18.26. Personalis Inc
  • 18.27. QIAGEN N V
  • 18.28. Quest Diagnostics Incorporated
  • 18.29. Thermo Fisher Scientific Inc
  • 18.30. Veracyte Inc

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CLINICAL EXOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CLINICAL EXOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CLINICAL EXOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CLINICAL EXOME SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ADULT EXOME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ADULT EXOME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ADULT EXOME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY PEDIATRIC EXOME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY PEDIATRIC EXOME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY PEDIATRIC EXOME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TARGETED GENE PANEL TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TARGETED GENE PANEL TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TARGETED GENE PANEL TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TARGETED GENE PANEL TESTING, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CANCER PANELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CANCER PANELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CANCER PANELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CANCER PANELS, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY HEMATOLOGIC PANELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY HEMATOLOGIC PANELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY HEMATOLOGIC PANELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SOLID TUMOR PANELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SOLID TUMOR PANELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SOLID TUMOR PANELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CARDIOVASCULAR PANELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CARDIOVASCULAR PANELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CARDIOVASCULAR PANELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NEUROLOGICAL DISORDER PANELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NEUROLOGICAL DISORDER PANELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NEUROLOGICAL DISORDER PANELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY INFECTIOUS DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY INFECTIOUS DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY INHERITED DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY INHERITED DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY INHERITED DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY INHERITED DISEASE, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY COMMON DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY COMMON DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY COMMON DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY RARE DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY RARE DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY RARE DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SOLID TUMOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SOLID TUMOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SOLID TUMOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY PHARMACOGENOMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY PHARMACOGENOMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY PHARMACOGENOMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY REPRODUCTIVE HEALTH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY REPRODUCTIVE HEALTH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY REPRODUCTIVE HEALTH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY REPRODUCTIVE HEALTH, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NONINVASIVE PRENATAL TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NONINVASIVE PRENATAL TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NONINVASIVE PRENATAL TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY PREIMPLANTATION GENETIC TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY PREIMPLANTATION GENETIC TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY PREIMPLANTATION GENETIC TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY DIRECT TO CONSUMER TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY DIRECT TO CONSUMER TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY DIRECT TO CONSUMER TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BGI SEQUENCING PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BGI SEQUENCING PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BGI SEQUENCING PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BGI SEQUENCING PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BGISEQ 500, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BGISEQ 500, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BGISEQ 500, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY MGISEQ, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY MGISEQ, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY MGISEQ, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ILLUMINA SEQUENCING PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ILLUMINA SEQUENCING PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ILLUMINA SEQUENCING PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ILLUMINA SEQUENCING PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY MISEQ, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY MISEQ, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY MISEQ, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NEXTSEQ, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NEXTSEQ, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NEXTSEQ, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NOVASEQ, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NOVASEQ, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY NOVASEQ, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY THERMO FISHER SEQUENCING PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY THERMO FISHER SEQUENCING PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY THERMO FISHER SEQUENCING PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY THERMO FISHER SEQUENCING PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ION TORRENT PGM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ION TORRENT PGM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ION TORRENT PGM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ION TORRENT PROTON, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ION TORRENT PROTON, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ION TORRENT PROTON, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY PLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY PLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SALIVA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SALIVA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SALIVA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TISSUE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TISSUE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TISSUE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TISSUE, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY FFPE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY FFPE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY FFPE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY FRESH FROZEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY FRESH FROZEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY FRESH FROZEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. AMERICAS NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 153. AMERICAS NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. AMERICAS NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CLINICAL EXOME SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 155. AMERICAS NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TARGETED GENE PANEL TESTING, 2018-2032 (USD MILLION)
  • TABLE 156. AMERICAS NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CANCER PANELS, 2018-2032 (USD MILLION)
  • TABLE 157. AMERICAS NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 158. AMERICAS NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 159. AMERICAS NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY INHERITED DISEASE, 2018-2032 (USD MILLION)
  • TABLE 160. AMERICAS NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 161. AMERICAS NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY REPRODUCTIVE HEALTH, 2018-2032 (USD MILLION)
  • TABLE 162. AMERICAS NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. AMERICAS NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 164. AMERICAS NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BGI SEQUENCING PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 165. AMERICAS NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ILLUMINA SEQUENCING PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 166. AMERICAS NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY THERMO FISHER SEQUENCING PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 167. AMERICAS NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. AMERICAS NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 169. AMERICAS NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TISSUE, 2018-2032 (USD MILLION)
  • TABLE 170. NORTH AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. NORTH AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CLINICAL EXOME SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TARGETED GENE PANEL TESTING, 2018-2032 (USD MILLION)
  • TABLE 174. NORTH AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CANCER PANELS, 2018-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 176. NORTH AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY INHERITED DISEASE, 2018-2032 (USD MILLION)
  • TABLE 178. NORTH AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY REPRODUCTIVE HEALTH, 2018-2032 (USD MILLION)
  • TABLE 180. NORTH AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 182. NORTH AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BGI SEQUENCING PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ILLUMINA SEQUENCING PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 184. NORTH AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY THERMO FISHER SEQUENCING PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. NORTH AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TISSUE, 2018-2032 (USD MILLION)
  • TABLE 188. LATIN AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. LATIN AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CLINICAL EXOME SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TARGETED GENE PANEL TESTING, 2018-2032 (USD MILLION)
  • TABLE 192. LATIN AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CANCER PANELS, 2018-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 194. LATIN AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY INHERITED DISEASE, 2018-2032 (USD MILLION)
  • TABLE 196. LATIN AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY REPRODUCTIVE HEALTH, 2018-2032 (USD MILLION)
  • TABLE 198. LATIN AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 200. LATIN AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BGI SEQUENCING PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ILLUMINA SEQUENCING PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 202. LATIN AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY THERMO FISHER SEQUENCING PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. LATIN AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TISSUE, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CLINICAL EXOME SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TARGETED GENE PANEL TESTING, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CANCER PANELS, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY INHERITED DISEASE, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY REPRODUCTIVE HEALTH, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BGI SEQUENCING PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ILLUMINA SEQUENCING PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY THERMO FISHER SEQUENCING PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TISSUE, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CLINICAL EXOME SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TARGETED GENE PANEL TESTING, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY CANCER PANELS, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY INHERITED DISEASE, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY REPRODUCTIVE HEALTH, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY BGI SEQUENCING PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY ILLUMINA SEQUENCING PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY THERMO FISHER SEQUENCING PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE NEXT GENERATION SEQUENCING CLIA LABORATORY SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE NEXT GENERATION SEQUENCIN